Drug intelligence / Profile preview

LY3451838

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LY3451838 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody developed by Eli Lilly. It potently and selectively binds to and neutralizes pituitary adenylate cyclase-activating polypeptide (PACAP), specifically targeting the PACAP38 isoform, which is implicated in migraine pathophysiology. By antagonizing the pituitary adenylate cyclase-activating polypeptide receptor, LY3451838 aims to prevent or reduce migraine attacks in patients who have not responded to other preventive treatments. The drug has reached phase II clinical trials for treatment-resistant migraine[1][3][7].

Other names: PACAP 38 antibodyPACAP38 antibodyPACAP-38 antibody

Targets

PACAP-38 (Pituitary adenylate cyclase-activating polypeptide-38)

Beyond the preview

Go deeper on LY3451838.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3451838.

Explore the full profile